Business Wire

ANA Chronicles 40 years of Japanese Video Game History with Dedicated Content

30.10.2019 18:00:00 EET | Business Wire | Press release

Share

All Nippon Airways (ANA), Japan’s largest 5-Star airline for seven consecutive years will launch new content, “IS JAPAN COOL? GAME CHRONICLE,” that focuses on Japanese game culture and seeks to increase awareness of Japan’s contributions to this growing industry. The content will be part of IS JAPAN COOL? website that is designed to promote international tourism in Japan. With the number of game-centric visitors to Japan on the rise, this website is a vital tool in planning travel itineraries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191030005402/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

"GAME CHRONICLE" (Graphic: Business Wire)

Video games are the combined product of creators’ imagination and developers’ passion. Japan has long been a trendsetter in video game design and this website offers tourists a crash course in the history of video games and their impact on Japanese culture.

“ANA seeks to act as an ambassador for Japan and its culture on the global stage, and the launch of this new website section will help drive tourism while providing an important educational resource for those interested in video games,” said Takashi Shiki, Senior Executive Vice President of ANA. “Like everything we do, IS JAPAN COOL? has always sought to set the gold standard for tourism websites, and this latest addition certainly goes above and beyond expectations. We invite all visitors to Japan by using IS JAPAN COOL? to help plan their trips.”

Available in English and Chinese, ANA first launched “IS JAPAN COOL?” in 2012 to make Japan more accessible while also introducing the nation’s unique culture and attractions to the world. In addition to its detailed explanation of Japanese culture, IS JAPAN COOL? offers local insight that helps tourists navigate during their visit to Japan. The website features insider information on cities and local prefectures including Tokyo, Okinawa, and Kyoto while providing detailed overviews of Japanese culture such as washoku (Japanese cuisine), contemporary arts, matsuri (festivals), as well as budo and geido (martial arts and performing/fine arts).

GAME CHRONICLE

This website focuses on Japanese game history at four different stages, breaking it down by decade to highlight achievements in the 1980s, 1990s, 2000s, and 2010s and discussing 100 key topics that exemplify each of the four eras. Giving achievement points for each article read and video watched, this website itself is even structured like a video game to give visitors a memorable experience as they learn more about Japanese video games.

Each decade has a distinct theme, with image resolution and music faithfully being reproduced to evoke the technical limitations and overall aesthetic of each era. This allows visitors to learn about advances in game technology in each era.

Visitors can also watch interviews featuring prominent game experts from developers and creators sharing their behind-the-scenes stories and insider perspectives to professional gamers who offer their views on the industry today. This compelling content is available only on the “IS JAPAN COOL? GAME CHRONICLE” website.

ANA embraces its Japanese roots and is proud to celebrate the many distinct aspects of its culture and history. Video games make up one of Japan’s most important modern culture exports and ANA seeks to welcome the next generation of tourists, particularly those with an interest in video games.

About ANA
Following the “Inspiration of Japan” high quality of service, ANA has been awarded the respected 5-Star rating every year since 2013 from SKYTRAX. ANA is the only Japanese airline to win this prestigious designation seven years in a row. Additionally, ANA has been recognized by Air Transport World as “Airline of the Year” three times in the past 10 years - 2007, 2013 and 2018, becoming one of the few airlines winning this prestigious award for multiple times.

ANA was founded in 1952 with two helicopters and has become the largest airline in Japan, as well as one of the most significant airlines in Asia, operating 82 international routes and 121 domestic routes. ANA offers a unique dual hub model which enables passengers to travel to Tokyo and connect through the two airports in the metropolitan Tokyo, NARITA and HANEDA, to various destinations throughout Japan, and also offers same day connections between various North American, Asian and Chinese cities.

ANA has been a member of Star Alliance since 1999 and has joint venture partnerships with United Airlines, Lufthansa German Airlines, Swiss International Airlines and Austrian Airlines.

Besides the full service and award winner carrier ANA, the ANA Group has two LCCs as consolidated subsidiaries, Vanilla Air Inc. and Peach Aviation Limited. The ANA Group carried 54.4 million passengers in FY2018, has approximately 43,000 employees and a fleet of 260 aircrafts. ANA is a proud launch customer and the biggest operator of the Boeing 787 Dreamliner.

For more information, please refer to the following link.
https://www.ana.co.jp/group/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

“GAME CHRONICLE” PR Office: AUR, Inc.
Ashita Iju (Mr.), Miyabi Ishida (Ms.)
TEL: +81-3-5545-3888
E-mail: ijc_pr-ml@aur.co.jp
Or
ANA Corporate Communications, TEL +81-3-6735-1111, publicrelations@ana.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye